Topic: cardiac stem cells
Harnessing macrophages that provide healing in response to inflammation could be a better approach to treating heart attack than stem cells have been.
A combination of cardiac muscle cells and epicardial cells derived from stem cells restored damaged heart tissue in a rat study.
The product of a merger of Pluriomics and Axiogenesis, iPSC company Ncardia has signed licensing deals with Roche and Evotec.
After three years, Johnson & Johnson is ducking out of a partnership with Capricor focused on the use of stem cells to treat cardiovascular disease.
Scientists in North Carolina and Zhengzhou, China, have created a synthetic cardiac stem cell that functions like a natural stem cell, but with fewer risks.
Induced pluripotent stem cell (iPSC) specialist Axiogenesis AG has partnered with ion channel CRO Metrion Biosciences to develop human iPSC-derived cardiomyocytes and neurons for drug discovery applications.